This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OXiGENE To Present Data Showing Importance Of Local Site Pathology Confirmation In Phase 2/3 Clinical Trial Of Zybrestat(R) In Anaplastic Thyroid Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 7, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the presentation of data from the Phase 2/3 trial (FACT) of ZYBRESTAT in patients with anaplastic thyroid cancer (ATC), showing that patients enrolled in the trial had confirmed histologic diagnoses of ATC as indicated by site selected local pathology confirmation and a high rate of reliability and concordance with a second, independent central pathology review conducted prior to patient enrollment. These findings underscore the feasibility of utilizing local pathology confirmation of ATC in future clinical studies in ATC without the need for central pathology confirmation prior to patient enrollment, and indicate that a post-enrollment central review would provide the same degree of assurance. This should allow a more rapid enrollment of patients into future clinical trials in this indication. These data also confirm that patients with more favorable histologies were not enrolled in the study.

The poster will be presented on Sunday, September 9th at the 36th Annual Meeting of the European Thyroid Association in Pisa, Italy, and is titled, "Central Pathology Confirmation of Anaplastic Thyroid Cancer (ATC) in a Large Randomized Controlled Trial (FACT) Shows High Concordance with Site Designated Local Pathologist Confirmation," by Balkissoon et al.

Commented Jai Balkissoon, M.D., F.A.C.S., OXiGENE's Vice President of Clinical Development: "With a cancer as lethal and fast-progressing as ATC, it is critically important to ensure that patients are enrolled in the clinical trial as quickly as possible. The data to be presented from the Phase 2/3 FACT study on Sunday show the acceptability of using site selected local pathology confirmation to establish the diagnosis of ATC instead of mandating a pre-enrollment central pathology confirmation, which not only can cause enrollment delays but may prevent patients from entering the study altogether due to rapid disease progression or death. These data provide valuable insights that may be of significant value as we advance plans to conduct a pivotal registration trial in this indication."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%
TSLA $222.56 0.00%
YHOO $36.00 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs